Reactions 1680, p263 - 2 Dec 2017 Thrombocytopenia: case report In a retrospective cohort analysis of 167 patients, a patient [age and sex not stated] was described, who developed thrombocytopenia during treatment with octreotate- Lu-177-DOTA-Tyr-3 [ Lu-DOTATATE; duration of treatment to reaction onset not stated]. The patient, who had advanced neuroendocrine tumour, received treatment with 5550 to 7400 MBq (150 200 mCi) of octreotate-Lu-177-DOTA-Tyr-3 diluted in 48 to 50mL of sodium chloride [saline] and infused over 30 minutes with a flow rate of 1.6 mL/minute. The patient received octreotate- Lu-177-DOTA-Tyr-3 after 30 to 60 minutes from the start of amino acid infusion. Before the initiation of treatment, the patient had grade I thrombocytopenia. However, during the course of therapy, the patient exhibited further depletion in the platelet counts (86000 48000 /µL), which was considered as grade III thrombocytopenia. The patient’s decreased platelet count was managed with platelet transfusion. Author comment: "Treatment-related adverse events were analyzed in all the patients." "One patient presented with grade I thrombocytopenia at the time of recruitment and progressed to grade III toxicity." "The platelet counts in this patient were revived through platelet transfusion." Ballal S, et al. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients with Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study. Clinical Nuclear Medicine 42: e457-e466, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1097/ RLU.0000000000001816 - India 803284431 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera